Predicting the FSH Threshold Dose in Women with WHO Group II Anovulatory Infertility Failing to Ovulate or Conceive on Clomiphene Citrate

Overview

Journal Hum Reprod

Publisher Oxford University Press

Specialty Reproductive Medicine

Date 2008 Mar 29

PMID 18372254

Citations 6

Authors

Anders Nyboe Andersen

Adam Balen

Peter Platteau

Paul Devroey

Lisbeth Helmgaard

Joan-Carles Arce

Affiliations

Soon will be listed here.

Abstract

Unlabelled: BACKGROUND The objective of this investigation was to establish independent predictors of follicle-stimulating hormone (FSH) threshold dose in anovulatory women undergoing ovulation induction with FSH preparations.

Methods: One hundred and fifty-one patients with WHO Group II anovulatory infertility failing to ovulate or conceive on clomiphene citrate underwent ovarian stimulation with FSH-only preparations following a low-dose step-up protocol. The individual FSH threshold dose was defined as the FSH dose when meeting the human chorionic gonadotrophin criteria (one follicle > or =17 mm, or 2-3 follicles > or =15 mm). The influence of demographics, physical characteristics, obstetric and infertility and menstrual cycle history, ovarian ultrasonography, endocrine parameters and type of gonadotrophin preparation on the FSH threshold dose was assessed through multiple regression analysis.

Results: In the univariate analysis, age, body mass index (BMI), failure to ovulate with clomiphene citrate, menstrual cycle history (amenorrhea, oligomenorrhea or anovulatory cycles of 21-35 days), mean ovarian volume, LH/FSH ratio, testosterone and free androgen index were significant (P < 0.05) predictors of FSH threshold dose. In the multivariate analysis, menstrual cycle history, mean ovarian volume and BMI remained significant (P < 0.001).

Conclusions: The individual FSH threshold dose for ovulation induction in anovulatory women can be predicted based on three variables easily determined in clinical practice: menstrual cycle history, mean ovarian volume and BMI. A FSH dosage nomogram was constructed based on these parameters.

Citing Articles

Obesity and Polycystic Ovary Syndrome.

Kim J J Obes Metab Syndr. 2024; 33(4):289-301.

PMID: 39701598 PMC: 11704221. DOI: 10.7570/jomes24035.

Pilot study of the optimal protocol of low dose step-up follicle stimulating hormone therapy for infertile women.

Matsuzaki T, Iwasa T, Yanagihara R, Komasaka M, Yano K, Mayila Y Reprod Med Biol. 2018; 17(3):315-324.

PMID: 30013434 PMC: 6046519. DOI: 10.1002/rmb2.12208.

Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction.

Serour G, Aboulghar M, Al Bahar A, Hugues J, Esmat K Reprod Biol Endocrinol. 2014; 12:52.

PMID: 24942155 PMC: 4091767. DOI: 10.1186/1477-7827-12-52.

Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.

Legro R, Arslanian S, Ehrmann D, Hoeger K, Murad M, Pasquali R J Clin Endocrinol Metab. 2013; 98(12):4565-92.

PMID: 24151290 PMC: 5399492. DOI: 10.1210/jc.2013-2350.

Ovulation induction with minimal dose of follitropin alfa: a case series study.

Bruna-Catalan I, Menabrito M Reprod Biol Endocrinol. 2011; 9:142.

PMID: 22024419 PMC: 3214140. DOI: 10.1186/1477-7827-9-142.

References

Chan C, Ng E, Chan M, Tang O, Lau E, Yeung W . Bioavailability of hCG after intramuscular or subcutaneous injection in obese and non-obese women. Hum Reprod. 2003; 18(11):2294-7. DOI: 10.1093/humrep/deg446. View

Balasch J, Fabregues F, Creus M, Casamitjana R, Puerto B, Vanrell J . Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: a prospective, randomized trial of two starting doses in a chronic low-dose step-up protocol. J Assist Reprod Genet. 2001; 17(10):561-5. PMC: 3455454. DOI: 10.1023/a:1026433813702. View

Homburg R, Howles C . Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update. 1999; 5(5):493-9. DOI: 10.1093/humupd/5.5.493. View

van Santbrink E, Eijkemans M, Macklon N, Fauser B . FSH response-dose can be predicted in ovulation induction for normogonadotropic anovulatory infertility. Eur J Endocrinol. 2002; 147(2):223-6. DOI: 10.1530/eje.0.1470223. View

Calaf Alsina J, Ruiz Balda J, Romeu Sarrio A, Caballero Fernandez V, Cano Trigo I, Gomez Parga J . Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. BJOG. 2003; 110(12):1072-7. View

Coelingh Bennink H, Fauser B, Out H . Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized,.... Fertil Steril. 1998; 69(1):19-25. DOI: 10.1016/s0015-0282(97)00423-8. View

Balen A, Platteau P, Nyboe Andersen A, Devroey P, Helmgaard L, Arce J . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial. Hum Reprod. 2007; 22(7):1816-23. DOI: 10.1093/humrep/dem075. View

Steinkampf M, Hammond K, Nichols J, Slayden S . Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration. Fertil Steril. 2003; 80(1):99-102. DOI: 10.1016/s0015-0282(03)00566-1. View

Imani B, Eijkemans M, Faessen G, Bouchard P, Giudice L, Fauser B . Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril. 2002; 77(1):83-90. DOI: 10.1016/s0015-0282(01)02928-4. View

10.

Polson D, Kiddy D, Mason H, Franks S . Induction of ovulation with clomiphene citrate in women with polycystic ovary syndrome: the difference between responders and nonresponders. Fertil Steril. 1989; 51(1):30-4. DOI: 10.1016/s0015-0282(16)60423-5. View

11.

Platteau P, Nyboe Andersen A, Balen A, Devroey P, Sorensen P, Helmgaard L . Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod. 2006; 21(7):1798-804. DOI: 10.1093/humrep/del085. View

12.

van der Meer M, Hompes P, Scheele F, Schoute E, Veersema S, Schoemaker J . Follicle stimulating hormone (FSH) dynamics of low dose step-up ovulation induction with FSH in patients with polycystic ovary syndrome. Hum Reprod. 1994; 9(9):1612-7. DOI: 10.1093/oxfordjournals.humrep.a138761. View

13.

Imani B, Eijkemans M, Te Velde E, Habbema J, Fauser B . Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998; 83(7):2361-5. DOI: 10.1210/jcem.83.7.4919. View

14.

Lass A, Vassiliev A, Decosterd G, Warne D, Loumaye E . Relationship of baseline ovarian volume to ovarian response in World Health Organization II anovulatory patients who underwent ovulation induction with gonadotropins. Fertil Steril. 2002; 78(2):265-9. DOI: 10.1016/s0015-0282(02)03202-8. View

15.

Balen A, Platteau P, Andersen A, Devroey P, Sorensen P, Helmgaard L . The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization group II anovulatory infertility. BJOG. 2006; 113(10):1195-202. DOI: 10.1111/j.1471-0528.2006.01034.x. View

16.

Kiddy D, Watson H, Paterson C, Franks S . Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br J Obstet Gynaecol. 1992; 99(2):128-31. DOI: 10.1111/j.1471-0528.1992.tb14470.x. View

17.

Healy D, Trounson A, Andersen A . Female infertility: causes and treatment. Lancet. 1994; 343(8912):1539-44. DOI: 10.1016/s0140-6736(94)92941-6. View

18.

Yarali H, Bukulmez O, Gurgan T . Urinary follicle-stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate-resistant, normogonadotropic,chronic anovulation: a prospective randomized study. Fertil Steril. 1999; 72(2):276-81. DOI: 10.1016/s0015-0282(99)00209-5. View